key: cord-0715178-l47qjja1
authors: Teo, Shyh Poh
title: Ipsilateral Axillary Adenopathy from mRNA COVID-19 Vaccines
date: 2021-08-02
journal: Ann Geriatr Med Res
DOI: 10.4235/agmr.21.0057
sha: ba34559941bdb1c42877019d12c9cab401a0101e
doc_id: 715178
cord_uid: l47qjja1

nan

Geriatrics and Palliative Unit, Department of Internal Medicine, Raja Isteri Pengiran Anak Saleha (RIPAS) Hospital, Brunei Darussalam these symptoms closely mimicked those of metastasis and lasted for up to 6 weeks. However, lymph node biopsies confirmed vaccination-related reactive lymphadenopathy. 8) Patients presenting with unilateral axillary adenopathy should be evaluated for malignancy, particularly breast cancer. Adenopathy may also be incidentally identified on routine imaging studies, such as computed tomography of the thorax or breast magnetic resonance image. Clinicians should enquire regarding recent COVID-19 vaccination, as mRNA vaccines may induce ipsilateral axillary lymph node hyperplasia. Documentation of vaccine administration, such as date and location site, should also be reviewed, as ipsilateral lymphadenopathy in the setting of recent (within 6 weeks) vaccination may indicate a benign entity. 9) For patients with suspected vaccine-associated adenopathy and normal breast imaging, clinicians should consider watchful waiting, with a follow-up ultrasound to ensure resolution of lymphadenopathy performed 8 weeks after the second vaccine dose. This is a way to avoid unnecessary axillary lymph node biopsy. 6, 10) However, in patients with a family history of breast cancer or a suspicion of malignancy such as breast cancer or lymphoma, lymph node biopsies should still be performed. 11) If possible, routine imaging studies should be performed before vaccination. However, in the setting of the current pandemic, COVID-19 vaccination should not be delayed. Imaging studies should be performed without delay for urgent indications such as acute symptoms or the need for urgent treatment planning, but these procedures may be may be postponed for other indications until at least 6 weeks after the second vaccine dose. Patients with primary cancer, such as breast cancer or upper limb melanoma, should ideally have both vaccine doses administered on the contralateral side. 12) In conclusion, geriatricians should be aware that ipsilateral axillary adenopathy may represent an AEFI, particularly after the administration of mRNA COVID-19 vaccines. This condition usually occurs several days after vaccination and may last for up to 6

Review of COVID-19 vaccines and their evidence in older adults

Review of COVID-19 mRNA vaccines: BNT162b2 and mRNA-1273

COVID-19 vaccine developments and considerations for appraisal of the evidence

Local reactions, systemic reactions, adverse events, and serious adverse events: Moderna COVID-19 vaccine

Local reactions, systemic reactions, adverse events, and serious adverse events: Pfizer-BioNTech COVID-19 vaccine

Unilateral axillary Adenopathy in the setting of COVID-19 vaccine

Lymphadenopathy following COVID-19 vaccination: imaging findings review

Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncologic Patients

Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists across specialties

Management of Unilateral Axillary Lymphadenopathy Detected on Breast MRI in the Era of Coronavirus Disease (COVID-19) Vaccination

Regional lymphadenopathy following COVID-19 vaccination: considerations for primary care management

Multidisciplinary recommendations regarding post-vaccine adenopathy and radiologic imaging: Radiology Scientific Expert Panel